Phase 2 Lupus Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are 18 years of age or older.
• You have been diagnosed with Systemic Lupus Erythematosus (SLE/lupus) using recognised medical guidelines.
• A urine test has shown a certain level of protein in your urine (confirm with trial site), measured from a 24-hour urine sample taken within a specific timeframe before the study begins.
• You have had a kidney biopsy within the past 24 weeks showing a specific type and level of lupus-related kidney disease (lupus nephritis, certain classes with some level of activity) (confirm with trial site).

Who may not be able to join:

• You are unwilling or unable to give written consent or follow the study's rules and schedule.
• You cannot take the medication mycophenolate mofetil (MMF) or mycophenolate sodium, or the study doctor believes it is not appropriate for you.
• You have received certain biological or experimental treatments within roughly the last 3 months or more (depending on the specific drug), with the exception of a drug called belimumab.
• You have been treated with rituximab or a similar drug that reduces B cells in your immune system within the past 6 months.
• You have previously received the study drug VIB4920.
• You have had a live vaccine (such as some flu or travel vaccines) within the past 4 weeks.
• You currently need, or have frequently needed (3 or more times in the past year), steroid tablets or injections for another health condition.
• You currently have cancer, or have had cancer in the past, unless it was a minor skin cancer or early-stage cervical condition that was fully treated more than 12 months ago.
• Your kidneys are severely damaged, with kidney function below a certain level as measured by a blood test (confirm with trial site).
• You have had an organ or tissue transplant at any point.
• You have recently had a blood clot in a vein or artery, or have had major surgery or been unable to move around for a long period within the past 12 weeks.
• You have a hereditary condition affecting blood clotting (such as a deficiency in antithrombin III, protein S, or protein C).
• You have been diagnosed with antiphospholipid syndrome (a condition that increases the risk of blood clots).
• You have had a severe allergic reaction to any ingredient in the study drug VIB4920.
• Certain blood test results fall outside acceptable ranges, including very low levels of certain immune cells, low red blood cells, low platelets, or raised liver enzymes (confirm with trial site).
• There is evidence you currently have or have previously had a tuberculosis (TB) infection, based on specific tests.
• You have HIV.
• You currently have or have previously had hepatitis B.
• You currently have or have previously had hepatitis C, unless it was successfully and fully treated.
• You currently have an active infection of any kind (bacterial, viral, fungal, or other).
• You have a history of serious, repeated, or long-term infections that the study doctor believes may put you at extra risk.
• You have a history of a serious psychiatric condition that the study doctor believes would make it difficult for you to take part safely.
• You are currently misusing substances, or have done so in the past 12 months.
• You do not have a suitable vein for receiving intravenous (drip) treatment.
• You are currently pregnant.
• You are currently breastfeeding.
• You are unwilling to use an acceptable form of contraception for the full duration of the study (this applies to women who could become pregnant, and to men whose partners could become pregnant).
• You have any other medical condition, test result, or health concern that the study doctor believes could put you at risk or affect the study results.

Important: Always verify eligibility with the trial site directly before applying.